Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

By Lahu Gezim   Hünnemeyer Andreas  

Clinical Pharmacokinetics, Vol. 49, Iss. 9, 2010-09 ,pp. : 589-606

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of losartan

By Burnier Michel   Wuerzner Gréégoire  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 5, 2011-05 ,pp. : 643-649

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of zoledronic acid

By De Luca Antonella   Lamura Luana   Gallo Marianna   Daniele Gennaro   D'Alessio Amelia   Giordano Pasqualina   Maiello Monica Rosaria   Pergameno Maria   Perrone Francesco   Normanno Nicola  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 7, 2011-07 ,pp. : 911-918

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of etravirine

By Dickinson Laura   Khoo Saye   Back David  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 12, 2010-12 ,pp. : 1575-1585

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of pramipexole

By Antonini Angelo   Calandrella Daniela  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 10, 2011-10 ,pp. : 1307-1314

Informa Healthcare

Access to resources Recommend Favorite